BMAC-HARVEST: Innovational Method in Osteoarticular Pathology Using Autogenous Stem Cells

2015 ◽  
Vol 638 ◽  
pp. 280-285
Author(s):  
Sólyom Árpád ◽  
Király Ildikó ◽  
Benedek Csaba ◽  
Nagy Ors ◽  
Solyom Reka ◽  
...  

Introduction: BMAC-Harvest is an innovational method regarding autogenous stem cell treatments in various fields of medicine. In osteoarticular pathology it is used for treating chronic pathology cases as well as acute and traumatic ones. Purpose: The purpose of this study was to represent the clinical and imaging results of the patients presented to the Ist Orthopedic and Traumatology Clinic of Targu Mures. The results were obtained in the period 2012-2014 after using BMAC-Harvest autologous stem cells. Material and method: For this study the authors have included 28 patients from the Ist Orthopaedic and Traumatology Clinic of Targu Mures, suffering from different musculoskeletal pathologies. The method used on these patients was a surgical treatment, which consisted of injecting BMAC-Harvest autogenous stem cells in a unique dosage. The procedure was conducted in the operating room in sterile conditions. These cells were extracted from the iliac crest after appropriate preparation and general anesthezia. Patients were evaluated from a clinical and imaging point of view at periods of 3, 6 and 12 months after treatment. In the evaluation the following aspects were monitorized in the form of questionnaires: level of satisfaction, mobility and the daily activities of patients. The pain intensity of the patients was measured by using the VAS scale (visual analog scale). For imaging representations the authors used standard radiography and IRM in 2 occurrences and have taken into account every sign which appeared after the treatment.Results: The satisfaction level of the patients was significantly increased after the 12th month evaluation compared to results after 3rd month. The pain got considerably reduced and most of the patients could resume their activity from before the treatment. 4 patients have reported mild and medium pain 12 months after the treatment. Conclusion: Autogenous stem cell treatment is an innovational technique with satisfying results for short and medium periods. The BMAC-Harvest autogenous stem cells can be used with clear indications in locomotor organ pathology and it can help in the recuperation of the patient after a trauma. The BMAC-Harvest autogenous stem cells increase the formation of callus after a fracture or pseudoarthrosis. This is an innovational procedure and it can be used successfully in osteoarticular pathology both chronic and acute.

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Yuan Li ◽  
Qi-lin Jiang ◽  
Leanne Van der Merwe ◽  
Dong-hao Lou ◽  
Cai Lin

Abstract Background A skin flap is one of the most critical surgical techniques for the restoration of cutaneous defects. However, the distal necrosis of the skin flap severely restricts the clinical application of flap surgery. As there is no consensus on the treatment methods to prevent distal necrosis of skin flaps, more effective and feasible interventions to prevent skin flaps from necrosis are urgently needed. Stem therapy as a potential method to improve the survival rate of skin flaps is receiving increasing attention. Methods This review followed the recommendations from the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statements. Twenty studies with 500 animals were included by searching Web of Science, EMBASE, PubMed, and Cochrane Library databases, up until October 8, 2020. Moreover, the references of the included articles were searched manually to obtain other studies. All analyses were conducted using Review Manager V.5.3 software. Results Meta-analysis of all 20 studies demonstrated stem cell treatment has significant effects on reducing necrosis of skin flap compared with the control group (SMD: 3.20, 95% CI 2.47 to 3.93). Besides, subgroup analysis showed differences in the efficacy of stem cells in improving the survival rate of skin flaps in areas of skin flap, cell type, transplant types, and method of administration of stem cells. The meta-analysis also showed that stem cell treatment had a significant effect on increasing blood vessel density (SMD: 2.96, 95% CI 2.21 to 3.72) and increasing the expression of vascular endothelial growth factor (VEGF, SMD: 4.34, 95% CI 2.48 to 6.1). Conclusions The preclinical evidence of our systematic review indicate that stem cell-based therapy is effective for promoting early angiogenesis by up regulating VEGF and ultimately improving the survival rate of skin flap. In summary, small area skin flap, the administration method of intra-arterial injection, ASCs and MSCs, and xenogenic stem cells from humans showed more effective for the survival of animal skin flaps. In general, stem cell-based therapy may be a promising method to prevent skin flap necrosis.


2013 ◽  
Vol 2013 ◽  
pp. 1-17 ◽  
Author(s):  
Hakan Orbay ◽  
Hiroshi Mizuno

Neuromuscular diseases are a heterogeneous group of diseases that lead to significant disability in effected individuals. Pharmacological treatments failed to provide any significant improvement to date. Recently, the introduction of stem cells into the field of health sciences raised the hopes for a new treatment for neuromuscular diseases. In theory, stem cells, owing to their multilineage differentiation capacity, could differentiate into myofibers and neurons and replace the degenerated cells leading to recovery of the patients. Results obtained from the preclinical studies supported this theory. However, clinical trials with stem cells could not meet the expectations mainly because of early mortality, limited migration, and differentiation of the implanted cells. Modification of the stem cells before implantation, such as introduction of deficient genes or commitment to a precursor cell line provided little improvement. The biggest barrier to overcome for a successful of stem cell treatment, which also should be the focus of the future studies, is to increase the functional integration of the donor cells with the recipient tissues. Understanding the underlying pathogenic mechanisms of the neuromuscular diseases is essential to achieve this goal.


Author(s):  
Leelavathy Budamakuntla ◽  
Eswari Loganathan ◽  
Shwetha Suryanarayana ◽  
Aparna Dongre

<p class="abstract"><strong>Background:</strong> Androgenetic alopecia has been a stressful condition for the patients and treating dermatologists alike. With the advent of stem cell therapy in various diseases, and lot of controversies and ethical issues related to it, mesenchymal stem cells MSC have passed the acid test successfully, though with many challenges. Since the stem cells in the hair follicle bulge and the dermal papilla play an important role in hair cycle and growth, introducing an external source of neonatal mesenchymal stem cells seems to be a possibility in the treatment of AGA. Aims: To know the benefits and safety of stem cell treatment in patients who underwent mesotherapy with neonatal MSC in order to establish the safety and efficacy in the treatment of AGA.</p><p class="abstract"><strong>Methods:</strong> We collected data of 40 patients treated with mesoinjections of commercially prepared neonatal MSC, with AGA of grade 2 to 7. Before and after photographs, Patient (PtGA) and Physician (PGA) Global assessment scores were used to evaluate the treatment response.</p><p class="abstract"><strong>Results:</strong> We found that 70% of the patients showed a mild response and 25% of them showed a moderate improvement in the hair growth and reduction in hair loss after 4 sittings of monthly duration. One subject showed an improvement of 72%. Patients had 6 month follow up. No major adverse events were observed.</p><p class="abstract"><strong>Conclusions:</strong> Since this is an observational study, large randomized controlled studies, with longer follow ups is recommended to make MSC therapy a novel treatment option for AGA. </p><strong>Keywords: </strong>Mesenchymal stem cells, Mesotherapy, Androgenetic alopecia


2019 ◽  
Vol 20 (8) ◽  
pp. 1879 ◽  
Author(s):  
Marco Tatullo ◽  
Bruna Codispoti ◽  
Francesco Paduano ◽  
Manuel Nuzzolese ◽  
Irina Makeeva

Human oral-derived stem cells can be easily obtained from several oral tissues, such as dental pulp, periodontal ligament, from gingiva, or periapical cysts. Due to their differentiation potential, oral-derived mesenchymal stem cells are promising for tissue engineering and regenerative medicine. The regenerative ability showed by some oral tissues strongly depends on their sleeping adult stem cell populations that are able to repair small defects and to manage local inflammation. To date, researchers are working on effective and efficient methods to ensure safe and predictable protocols to translate stem cell research into human models. In the last decades, the challenge has been to finally use oral-derived stem cells together with biomaterials or scaffold-free techniques, to obtain strategic tools for regenerative and translational dentistry. This paper aims to give a clear point of view on state of the art developments, with some exciting insights into future strategies.


2018 ◽  
Vol 11 (1) ◽  
pp. 11-22 ◽  
Author(s):  
Omar M. E. Abdel-Salam ◽  
Amany A. Sleem ◽  
Eman R. Youness ◽  
Nadia A. Mohammed ◽  
Enayat A. Omara

We studied the effect of bone marrow-derived stem cells (BM-SCs) on oxidative stress, inflammation and pathological changes induced in the brain and liver of mice by the antipsychotic drug haloperidol. Mice were intraperitoneally (i.p.) treated with haloperidol at 5 mg/kg for 3 consecutive days followed by i.p. stem cell suspension and euthanized 24h later. Haloperidol resulted in increased brain and liver malondialdehyde (MDA) and nitric oxide contents together with decreased reduced glutathione (GSH). There were also decreased paraoxonase-1 (PON-1) activity in brain and liver and increased interleukin-1β (IL-1 β), interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) in brain tissue. Haloperidol produced neuronal necrosis and apoptosis and the appearance of esinophilic areas and strong TNF-α immunoreactivity in the cerebral cortex and striatum of treated mice. In the liver, centrilobular necrosis, inflammatory cell infiltration and sinusoidal haemorrhage were observed. In haloperidol-treated mice, stem cell injection had no significant effects on brain and liver levels of MDA, nitric oxide or GSH. Paraoxonase-1 activity in brain, however, decreased by stem cells application. In brain, there were decreased IL-1β, IL-6 and TNF-α. Brain neurodegenerative changes, brain TNF-immunoreactivity and histological liver damage were all markedly ameliorated after stem cell treatment. These results indicate that stem cells protect against brain and liver toxicity caused by short term haloperidol treatment in high dose. The protective effects of stem cell treatment is likely to result from interfering with cytokine release.


2013 ◽  
Vol 52 (05) ◽  
pp. 192-197 ◽  
Author(s):  
B.-N. Park ◽  
J.-K. Yoon ◽  
Y.-S. An

SummaryAim: This study was performed to evaluate the effects of intravenously transplanted rat bone-marrow derived mesenchymal stem cells (rBMSCs) in an acute brain trauma model using serial 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) in rat models. Animals, methods: Trauma models were made using a controlled cortical impact injury device. The stem cell treatment group was treated with intravenous injections of BMSCs, and models without stem cell therapy comprised the control group. Serial 18F-FDG PET images were obtained 1, 7, 14, 21, and 28 days after trauma. The difference in 18F-FDG uptake between day 1 and each time point after trauma was analyzed with SPM2 (uncorrected p < 0.005). Results: The stem cell treatment group demonstrated significantly higher 18F-FDG uptake in the right parietal region at 14 days after trauma than at 1 day after trauma. An increase in glucose metabolism in the right parietal cortex appeared on days 21 and 28 after trauma in the group without stem cell treatment. The 18F-FDG uptake in the brain was improved over a broader area, including the right parietal and right primary somatosensory cortex, on days 21 and 28 after trauma in the stem cell treatment group compared with the group without stem cell treatment. Conclusion: BMSC therapy in trauma models led to improved glucose metabolism. This result might support the therapeutic effect of stem cells in brain trauma.


Sign in / Sign up

Export Citation Format

Share Document